Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Preoperative Chemotherapy
100%
Cisplatin
100%
Triple Negative
100%
Rucaparib
100%
BRCA-associated Breast Cancer
100%
Triple-negative Breast Cancer
42%
Disease-free Survival
42%
Neoadjuvant Therapy
28%
High-risk Population
28%
BRCA mutation
28%
High Risk
14%
Patient-completed
14%
Breast
14%
Dose Reduction
14%
Lymph Node
14%
Lymph Node Involvement
14%
Tumor Size
14%
Chemotherapy Alone
14%
Genetic Testing
14%
Recurrence Risk
14%
Invasive Disease
14%
Resource Utilization
14%
Germline mutation
14%
Residual Disease
14%
BRCA2 mutation
14%
Burden Test
14%
Median Effective Concentration
14%
DNA-damaging
14%
PARP Inhibitors (PARPi)
14%
Deleterious mutations
14%
Residual Cancer Burden
14%
Medicine and Dentistry
Breast Cancer
100%
Cisplatin
100%
Preoperative Chemotherapy
100%
Rucaparib
100%
Disease Free Survival
42%
Triple Negative Breast Cancer
42%
Lymph Node
28%
Neoadjuvant Therapy
28%
High Risk Population
28%
Malignant Neoplasm
14%
Neoplasm
14%
Infusion
14%
Arm
14%
Low Drug Dose
14%
Recurrent Disease
14%
BRCA1
14%
Genetic Screening
14%
Minimal Residual Disease
14%
Germline Mutation
14%
BRCA2
14%
Drug Dose Reduction
14%
Poly ADP Ribose Polymerase
14%
BRCA Mutation
14%
Diseases
14%
Chemotherapy
14%
Immunology and Microbiology
Disease Free Survival
100%
Lymph Node
66%
High Risk Population
66%
Low Drug Dose
33%
Arm
33%
Tumor Volume
33%
Genetic Screening
33%
Germline Mutation
33%
Drug Dose Reduction
33%
Biochemistry, Genetics and Molecular Biology
Cisplatin
100%
Disease Free Survival
42%
High Risk Population
28%
BRCA1
14%
Low Drug Dose
14%
Genetic Screening
14%
Tumor Volume
14%
Germline Mutation
14%
BRCA2
14%
Poly ADP Ribose Polymerase
14%
Drug Dose Reduction
14%